Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing R...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: October 2, 2023

Postpartum Support International Observes Pregnancy and Infant Loss Awareness Month • Electra Extends Processing of Black Mass Material Based on Successes of Its Battery Recycling Trial • New Esri Book Provides Accessible Understanding of the Most Widely Used ArcGIS Spatial Statistics Tools • Peekaboo Gender Test Announces Groundbreaking Clinical Study Results: Accurate Fetal Sex Determination at Just 6 Weeks of Pregna • Connie Health Expands Medicare Advisory Services to Georgia • Esri Releases New Guide for Readers with Little to No Previous Experience with ArcGIS Pro • Caring Transitions of Ambler Brings Much-Needed Services to Montgomery County • Boise State University’s Cyberdome Program Soars in First Year of Operation • Ameresco to Announce Third Quarter 2023 Financial Results on November 6, 2023 • Esri Book Teaches Human Geography Using Interactive Maps and Data for a Unique Perspective • ESFM USA® Wins Sustainability Award From International Facility Management Association for Impact of Energy Management Solut • New Edition of Esri's ArcGIS Pro Guide Is Revised and Streamlined for Learning Latest Workflows • RUSSELL INNOVATION CENTER FOR ENTREPRENEURS TO RECEIVE $800K GRANT • Make-A-Wish® and BuzzRx® celebrate 10 years of partnership in support of children with critical illnesses • SourceAmerica Promotes Workforce Inclusion for People with Disabilities During National Disability Employment Awareness Month • BACARDÍ® Rum Inaugurates System to Cut Greenhouse Gas Emissions by 50% • Solving the Childcare Crisis One Step at a Time: A Marketplace of Employer-Backed Educational Programs • Meijer enhances its health and wellness customer experience by partnering with Blue Cross Blue Shield of Michigan on a Medicare • Ink Different Tattoos Teams Up With The Red Cross For "Holiday For Heroes" Nationwide Campaign To Support The Armed Service Memb • SageSure Earns Industry Accolades for Underwriting Performance and Culture

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif. , June 10 /Businesswire/ - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 9, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 43,150 shares of common stock and 22,030 restricted stock units (“RSUs”) to nine new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price per share equal to $28.40 per share, Mirum’s closing trading price on June 9, 2023, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees’ continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum’s 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI^® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome three months of age and older, and in Europe for the same indication in patients two months of age and older.

Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months and older and in Europe in PFIC for patients two months and older.

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.

Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in two potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.

Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.